Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX)

Marcello Marino, Diego Rizzotti, Sergio Leonardi

Research output: Contribution to journalArticle

Abstract

Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.

Original languageEnglish
JournalCurrent Cardiology Reports
Volume16
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Percutaneous Coronary Intervention
Pharmaceutical Preparations
clopidogrel
Purinergic P2Y Receptor Antagonists
Thienopyridines
Proxy
Stents
Thrombosis
Blood Platelets
Myocardial Infarction
cangrelor
Therapeutics
Population

Keywords

  • Acute coronary syndrome
  • Cangrelor
  • CHAMPION Programme
  • Percutaneous coronary interventions
  • Platelet inhibition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Cangrelor : Review of the Drug and the CHAMPION Programme (Including PHOENIX). / Marino, Marcello; Rizzotti, Diego; Leonardi, Sergio.

In: Current Cardiology Reports, Vol. 16, No. 6, 2014.

Research output: Contribution to journalArticle

@article{9a715ed8044748a788ac0e16c949aaf1,
title = "Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX)",
abstract = "Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.",
keywords = "Acute coronary syndrome, Cangrelor, CHAMPION Programme, Percutaneous coronary interventions, Platelet inhibition",
author = "Marcello Marino and Diego Rizzotti and Sergio Leonardi",
year = "2014",
doi = "10.1007/s11886-014-0493-4",
language = "English",
volume = "16",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Cangrelor

T2 - Review of the Drug and the CHAMPION Programme (Including PHOENIX)

AU - Marino, Marcello

AU - Rizzotti, Diego

AU - Leonardi, Sergio

PY - 2014

Y1 - 2014

N2 - Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.

AB - Platelet inhibition is the main goal of ancillary pharmacologic therapy during percutaneous coronary interventions (PCI). Thienopyridines and ticagrelor are oral drugs developed for this purpose. Cangrelor is an intravenous, non-thienopyridine antagonist of the P2Y12 receptor with a rapid, potent, predictable, and quickly reversible effect. Cangrelor has been studied in a broad population intended to receive PCI in the CHAMPION program, where it was compared with different clopidogrel regimens. The first two trials, CHAMPION PCI and PLATFORM, failed their primary objective, likely for challenges in the adjudication of PCI-related myocardial infarction. In a third trial that implemented the universal definition of MI, CHAMPION PHOENIX, a reduction of thrombotic events, including stent thrombosis, was observed. In the BRIDGE trial cangrelor has been studied in patients who had to prematurely interrupt antiplatelet therapy for surgery. Cangrelor appears a promising agent in patients who require PCI or when a rapid reversal is needed.

KW - Acute coronary syndrome

KW - Cangrelor

KW - CHAMPION Programme

KW - Percutaneous coronary interventions

KW - Platelet inhibition

UR - http://www.scopus.com/inward/record.url?scp=84901583236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901583236&partnerID=8YFLogxK

U2 - 10.1007/s11886-014-0493-4

DO - 10.1007/s11886-014-0493-4

M3 - Article

C2 - 24879371

AN - SCOPUS:84901583236

VL - 16

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

ER -